Dapagliflozin Propanediol/Metformin Hydrochloride

达格列净丙二醇/盐酸二甲双胍

Report date: 2024/08/16 17:16:58

Base Information

Drug NameDapagliflozin Propanediol/Metformin Hydrochloride
Drug Alias NameMetformin Hydrochloride/Dapagliflozin Propanediol达格列净丙二醇一水合物/盐酸二甲双胍达格列净二甲双胍Metformin Hydrochloride/Dapagliflozin Propanediol MonohydrateDapagliflozin Propanediol Monohydrate/Metformin Hydrochloride +[10] 
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Sodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2014/01/16
Country/TerritoryUnited StatesSwedenSouth Korea +[5] 
CombinationsYes Metformin HydrochlorideDapagliflozin Propanediol Monohydrate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca PlcBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Ab
Inactive CompaniesHanmi Pharmaceutical Co LtdBristol Myers Squibb SrlcompanyAstrazeneca Plc
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD15
Related LinksKEGG